Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Preferred Stock Liabilities (2023 - 2025)

Onconetix (ONCO) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $64.2 million as the latest value for Q2 2024.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $64.2 million in Q2 2024 year-over-year; TTM through Jun 2024 was $64.2 million, a N/A change, with the full-year FY2023 number at $64.2 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $64.2 million for Q2 2024 at Onconetix, roughly flat from $64.2 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $64.2 million in Q4 2023 to a low of $64.2 million in Q4 2023.